His primary scientific interests are in Phagocytosis, Immunology, Receptor, Microbiology and Protein kinase A. His Phagocytosis research also works with subjects such as
His work deals with themes such as Tumor necrosis factor alpha, Prostaglandin E2, Prostaglandin E, Signal transduction and Systemic inflammation, which intersect with Receptor. His work on Clostridium difficile as part of his general Microbiology study is frequently connected to Macrophage receptor with collagenous structure, thereby bridging the divide between different branches of science. The concepts of his Protein kinase A study are interwoven with issues in NADPH oxidase and Lipid signaling.
His primary areas of study are Microbiology, Immunology, Internal medicine, Clostridium difficile and Receptor. His biological study spans a wide range of topics, including Streptococcus, Streptococcus agalactiae and Virulence. David M. Aronoff combines subjects such as Gastroenterology, Endocrinology and Surgery with his study of Internal medicine.
His research in Clostridium difficile intersects with topics in Gut flora, Colitis, Colectomy, Ribotyping and Diarrhea. In his research on the topic of Receptor, Biochemistry is strongly related with Cell biology. As a part of the same scientific study, David M. Aronoff usually deals with the Phagocytosis, concentrating on Alveolar macrophage and frequently concerns with Pneumococcal pneumonia.
His main research concerns Microbiology, Innate immune system, Streptococcus, Macrophage and Immunology. His Microbiology study combines topics from a wide range of disciplines, such as Chorioamnionitis and Neonatal sepsis. As a member of one scientific family, David M. Aronoff mostly works in the field of Innate immune system, focusing on Virulence and, on occasion, Genotype, Phagocytosis and Antibody.
His Macrophage research integrates issues from Proinflammatory cytokine, Pathogen and Streptococcus agalactiae. His research links Clostridium difficile with Immunology. His Clostridium difficile study combines topics in areas such as Cyclooxygenase and Colitis.
David M. Aronoff mainly investigates 2019-20 coronavirus outbreak, Betacoronavirus, Coronavirus disease 2019, Immunology and Antibiotics. The study incorporates disciplines such as Pandemic and Severe acute respiratory syndrome coronavirus 2 in addition to 2019-20 coronavirus outbreak. Immunology is often connected to Clostridium difficile in his work.
David M. Aronoff interconnects Cyclooxygenase, Infectious Colitis, Gastrointestinal tract and Intestinal permeability in the investigation of issues within Clostridium difficile. His Antibiotics research is multidisciplinary, incorporating perspectives in Diabetic foot infections and Intensive care medicine. His Microbiology study which covers Virulence that intersects with Immune system.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Prostaglandin E2 Inhibits Alveolar Macrophage Phagocytosis through an E-Prostanoid 2 Receptor-Mediated Increase in Intracellular Cyclic AMP
David M. Aronoff;Claudio Canetti;Marc Peters-Golden.
Journal of Immunology (2004)
Cyclic AMP: master regulator of innate immune cell function.
Carlos H. Serezani;Megan N. Ballinger;David M. Aronoff;Marc Peters-Golden.
American Journal of Respiratory Cell and Molecular Biology (2008)
Fever and hypothermia in systemic inflammation: recent discoveries and revisions.
Andrej A Romanovsky;Maria C Almeida;David M Aronoff;Andrei I Ivanov.
Frontiers in Bioscience (2005)
Antipyretics: mechanisms of action and clinical use in fever suppression
David M Aronoff;Eric G Neilson.
The American Journal of Medicine (2001)
Determinants of the cellular specificity of acetaminophen as an inhibitor of prostaglandin H(2) synthases.
Olivier Boutaud;David M. Aronoff;Jacob H. Richardson;Lawrence J. Marnett.
Proceedings of the National Academy of Sciences of the United States of America (2002)
Cutting edge: macrophage inhibition by cyclic AMP (cAMP): differential roles of protein kinase A and exchange protein directly activated by cAMP-1.
David M. Aronoff;Claudio Canetti;Carlos H. Serezani;Carlos H. Serezani;Ming Luo.
Journal of Immunology (2005)
Microbiome Data Distinguish Patients with Clostridium difficile Infection and Non-C. difficile-Associated Diarrhea from Healthy Controls
Alyxandria M. Schubert;Mary A. M. Rogers;Cathrin Ring;Jill Mogle.
New insights into the mechanism of action of acetaminophen: Its clinical pharmacologic characteristics reflect its inhibition of the two prostaglandin H2 synthases
David M. Aronoff;David M. Aronoff;John A. Oates;John A. Oates;Olivier Boutaud;Olivier Boutaud.
Clinical Pharmacology & Therapeutics (2006)
The influence of non-steroidal anti-inflammatory drugs on the gut microbiome
Mary A.M. Rogers;David M. Aronoff.
Clinical Microbiology and Infection (2016)
Epidemiology of Clostridium difficile infection.
Daryl D. DePestel;David M. Aronoff.
Journal of Pharmacy Practice (2013)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: